Moderate

Major depressive disorder (MDD; clinical depression, unipolar depression)

Mood disorder · Psychiatry / Behavioural
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Persistent low mood and/or anhedonia >=2 weeks with neurovegetative features (sleep, appetite, energy, concentration, guilt, psychomotor change) causing functional impairment. ED role: identify, assess suicide/self-harm risk, exclude organic mimics, start/refer for treatment. Always screen for bipolarity (past mania/hypomania) before starting an antidepressant.

Red flags

  • Active suicidal ideation with plan/intent or recent attempt
  • Psychotic features (nihilistic/mood-congruent delusions) - needs psychiatry + antipsychotic
  • Severe self-neglect, refusal of food/fluids, catatonia
  • Postnatal onset (risk of puerperal psychosis) - urgent perinatal referral
  • New depression in elderly with cognitive change - exclude organic cause

Assessment

Differential diagnosis

  • Bipolar depression (ask re: past elevated mood - alters treatment)
  • Hypothyroidism / other endocrine (Addison, Cushing)
  • Anaemia, B12/folate deficiency
  • Substance/alcohol-induced mood disorder; medication-induced (steroids, interferon, propranolol)
  • Adjustment disorder / normal grief
  • Dementia / pseudodementia in the elderly
  • Occult malignancy, chronic pain, obstructive sleep apnoea

Investigations

  • PHQ-9 or HADS to quantify severity; risk assessment (ideation, plan, intent, means, protective factors)
  • FBC, U&E, LFT, TFT, glucose/HbA1c, calcium, B12/folate
  • Consider toxicology / alcohol history; collateral history
  • Review medications that can cause low mood

Management

  • 1. Assess and document suicide/self-harm risk FIRST; if high risk, do not discharge - urgent mental health / crisis team referral.
  • 2. Exclude organic causes (bloods above); treat reversible contributors.
  • 3. Screen for past mania/hypomania - if present, manage as bipolar (antidepressant monotherapy can precipitate mania).
  • 4. Classify severity (less severe vs more severe per NICE NG222).
  • 5. Less severe: offer guided self-help, CBT, group exercise; medication not first-line routinely.
  • 6. More severe: offer combination of antidepressant + psychological therapy; shared decision-making.
  • 7. Start SSRI first-line; review at 1-2 weeks (sooner if <25y or higher risk) for emergent suicidality/akathisia.
  • 8. Safety-net, signpost crisis lines, arrange GP/community mental health follow-up.

Drugs & doses

Sertraline 50 mg PO OD (start 25 mg if anxious; usual range 50-200 mg/day) - first-line SSRI
Citalopram 20 mg PO OD (max 40 mg; 20 mg if >65y or hepatic impairment - QTc caution) [verify local dose]
Fluoxetine 20 mg PO OD - preferred SSRI in under-18s (with psychological therapy)
Mirtazapine 15-45 mg PO nocte - alternative if insomnia/poor appetite
Venlafaxine 75 mg PO/day (modified-release; up-titrate) - second-line SNRI [verify local dose]
Avoid benzodiazepines for depression; avoid starting antidepressant if bipolar suspected

Disposition

Most managed in primary care/community mental health. Admit or refer to crisis team if high suicide risk, psychosis, severe self-neglect, or unable to keep safe. Arrange early review (within 1-2 weeks).

Complications & pitfalls

  • Suicide / self-harm
  • Switch to mania if antidepressant given in undiagnosed bipolar
  • Serotonin syndrome with interacting drugs
  • Chronicity / treatment resistance; social and occupational decline

Exam pearls

  • Always ask explicitly about suicidal thoughts - asking does not increase risk.
  • Warn about 1-2 week lag to benefit and possible early increase in anxiety/agitation.
  • Do not stop SSRIs abruptly (discontinuation syndrome) - taper.
  • Citalopram/escitalopram prolong QTc - check ECG if cardiac risk or polypharmacy.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.